The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 25, 2023
Filed:
Jan. 17, 2019
Applicant:
Aurigene Oncology Limited, Bangalore, IN;
Inventors:
Dinesh Chikkanna, Bangalore, IN;
Vinayak V. Khairnar, Nashik, IN;
Muralidhara Ramachandra, Bangalore, IN;
Leena Khare Satyam, Bangalore, IN;
Assignee:
AURIGENE ONCOLOGY LIMITED, Bangalore, IN;
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); C07C 237/24 (2006.01); C07C 275/26 (2006.01); C07C 311/11 (2006.01); C07D 205/04 (2006.01); C07D 207/16 (2006.01); C07D 211/58 (2006.01); C07D 211/72 (2006.01); C07D 231/56 (2006.01); C07D 261/04 (2006.01); C07D 295/215 (2006.01); C07D 333/28 (2006.01); C07D 401/04 (2006.01); A61K 31/496 (2006.01); A61P 35/00 (2006.01); A61K 31/17 (2006.01); A61K 31/439 (2006.01); A61K 31/4468 (2006.01); A61K 31/454 (2006.01); A61K 31/495 (2006.01); C07D 471/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 31/17 (2013.01); A61K 31/439 (2013.01); A61K 31/4468 (2013.01); A61K 31/454 (2013.01); A61K 31/495 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07C 237/24 (2013.01); C07C 275/26 (2013.01); C07C 311/11 (2013.01); C07D 205/04 (2013.01); C07D 207/16 (2013.01); C07D 211/58 (2013.01); C07D 211/72 (2013.01); C07D 231/56 (2013.01); C07D 261/04 (2013.01); C07D 295/215 (2013.01); C07D 333/28 (2013.01); C07D 401/04 (2013.01); C07D 471/08 (2013.01);
Abstract
The present invention relates to substituted alkynylene compounds represented by the compounds of formula (I), pharmaceutically acceptable salts and stereoisomers thereof. The present invention further provides the therapeutic uses of the compounds of formula (I) as anti-cancer agents.